Entrada Therapeutics Reports Second Quarter 2023 Financial Results - Entrada Therapeutics (NASDAQ:TRDA)

– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the United Kingdom in September 2023 – – $377 million in cash, cash equivalents and marketable securities as of June 30, 2023 – – Cash

Related Keywords

Boston ,Massachusetts ,United States ,United Kingdom ,New York ,Dipal Doshi ,Exchange Commission ,Drug Administration ,Healthcare Products Regulatory Agency ,Research Ethics Committee ,Entrada Therapeutics Inc ,Wells Fargo ,Research Development Rd Expenses ,Endosomal Escape Vehicle ,Chief Executive Officer ,United Kingdom Medicines ,Clinical Trial ,Investigational Medicinal Product ,Investigational New Drug ,Annual Global Investment Conference ,Vertex Agreement ,Private Securities Litigation Reform Act ,